Register Login
Register to leave comments
  • News bot May 7, 2026, 11:06 a.m.

    📋 AMYLYX PHARMACEUTICALS, INC. (AMLX) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 07:02:56

    Event Type: Financial Results

    Event Details:

    AMYLYX PHARMACEUTICALS, INC. (AMLX) Reports the reporting period Financial Results AMYLYX PHARMACEUTICALS, INC. (AMLX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 279768
      • anticipated in the third quarter of 2026
      • targeting calpain-2 with FDA Fast Track Designation for the potential treatment of amyotrophic lateral sclerosis (ALS), in March 2026
      • anticipated in Q3 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Assets Cash Equivalents Marketable Securities 279.77K 316.98K $-37.21K -11.74%
    Assets Prepaid Expenses Other Current Assets 5.26K 6.69K $-1.44K -21.46%
    Assets Other Assets 8.58K 8.97K $-395.00 -4.40%
    Operating Expenses Selling General Administrative 16.17K 15.68K $485.00 +3.09%
    Operating Expenses Loss From Operations 43.78K 37.80K $5.98K +15.81%
    Operating Expenses Other Income Net 2.50K 1.90K $599.00 +31.59%
    Operating Expenses Net Loss 41.28K 35.91K $5.38K +14.97%
    Operating Expenses Net Loss Per Share 0.37 0.42 $-0.05 -11.90%
    Operating Expenses Weighted Average Shares 110.56M 85.70M $24.87M +29.02%
    Cash and Marketable Securities 279.77K 316.98K $-37.21K -11.74%
    Prepaid Expenses and Other Current Assets 5.26K 6.69K $-1.44K -21.46%
    Other Assets 8.58K 8.97K $-395.00 -4.40%
    Accounts Payable 14.81K 21.43K $-6.62K -30.88%
    Selling, General & Administrative 16.17K 15.68K $485.00 +3.09%
    Loss from Operations 43.78K 37.80K $5.98K +15.81%
    Other Income, Net 2.50K 1.90K $599.00 +31.59%
    Net Loss 41.28K 35.91K $5.38K +14.97%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AMYLYX PHARMACEUTICALS, INC.
    • Ticker Symbol: AMLX

Search

News categories